Association between daily @entity413 fluctuation and coronary plaque properties in @entity1 receiving adequate lipid-lowering therapy assessed by continuous XXXX monitoring and optical coherence tomography.

@entity1 @entity2299 @entity4053 @entity14391 @entity1856 @entity453 @entity413
BACKGROUND: @entity413 fluctuation has been recognized as a residual risk apart from @entity2299 for the development of @entity453 ( @entity453 ). This study aimed to investigate the association between @entity413 fluctuation and coronary plaque morphology in @entity453 @entity1 . METHODS: This prospective study enrolled 72 consecutive @entity453 @entity1 receiving adequate lipid-lowering therapy. They were divided into 3 tertiles according to the mean amplitude of glycemic excursions (MAGE), which represents @entity413 fluctuation, measured by continuous @entity413 monitoring (tertile 1; <49.1, tertile 2; 49.1   ~   85.3, tertile 3; >85.3). Morphological feature of plaques were evaluated by optical coherence tomography. @entity14391 ( @entity14391 ) (mean lipid arc   *   length), fibrous cap thickness (FCT), and the prevalence of thin-cap @entity1856 (TCFA) were assessed in both culprit and non-culprit lesions. RESULTS: In total, 166 lesions were evaluated. @entity14391 was stepwisely increased according to the tertile of MAGE (1958        974 [tertile 1] vs. 2653        1400 [tertile 2] vs. 4362        1858 [tertile 3], p <0.001), whereas FCT was the thinnest in the tertile 3 (157.3        73.0   m vs. 104.0        64.1   m vs. 83.1        34.7   m, p <0.001, respectively). The tertile 3 had the highest prevalence of TCFA. Multiple linear regression analysis showed that MAGE had the strongest effect on @entity14391 and FCT (standardized coefficient b   =   0.527 and -0.392, respectively, both P <0.001). Multiple logistic analysis identified MAGE as the only independent predictor of the presence of TCFA (odds ratio 1.034; P <0.001). CONCLUSIONS: @entity413 fluctuation and @entity4053 may impact the formation of lipid-rich plaques and thinning of fibrous cap in @entity453 @entity1 with lipid-lowering therapy.
